Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://figshare.com/articles/dataset/Table_1_from_Camizestrant_in_Combination_with_Three_Globally_Approved_CDK4_6_Inhibitors_in_Women_with_ER_HER2_Advanced_Breast_Cancer_Results_from_SERENA-1/30363315
下载链接
链接失效反馈官方服务：
资源简介：
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.
创建时间：
2025-10-15
